T1	Participants 52 97	patients with pulmonary arterial hypertension
T2	Participants 172 223	patients with pulmonary arterial hypertension (PAH)
T3	Participants 505 522	patients with PAH
T4	Participants 895 964	98 randomized patients, 61% were WHO functional class II at baseline.
